RxDoctor Payments Data

Ashish Pershad, MD

Interventional Cardiology · Chandler, AZNPI 1194710657

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medtronic at 34.0% of the total. Reporting peaked in 2021 at $38,600 and has fallen 82.8% since, to $6,655 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$112,249in general payments, 2019–2025

Across 417 payments — averaging $269.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$38K
  • Edwards Lifesciences$24K
  • Philips North America LLC$14K
  • Asahi Intecc USA, Inc.$11K
  • Abiomed$5K
  • Abbott$4K
  • plus $16K from 27 others
$1,282,306in research payments, 2019–2025

Across 137 payments — averaging $9359.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$641K
  • Abbott$415K
  • Boston Scientific$226K

What the payments were for

  • Consulting fees$25,15022%
  • Speaking & faculty fees$54,51349%
  • Grants$1,0981%
  • Travel & lodging$12,94012%
  • Food & beverage$18,51516%
  • Entertainment$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$112,249 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$115,104
Medicare patients
303
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate33$306
Atorvastatin Calcium13$98
Carvedilol13$77

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →